Genesis Nz FPO Nzx
2.1100
22-December-24 22:34:26
20 minutes delayed
Stocks
+0.1000
+4.98%
Today's range
2.0100 - 2.1200
ISIN
NZGNEE0001S7
Source
ASX
-
Futures Flat As Markets Wind Down For 2024
23 Dec 2024 07:46:24 By Buzz FX
-
Citigroup Reaffirms Buy Rating for Cosan (NYSE:CSAN)
23 Dec 2024 07:46:12 By Buzz FX
-
Loop Capital Issues Positive Forecast for Klaviyo (NYSE:KVYO) Stock Price
23 Dec 2024 07:46:12 By Buzz FX
-
Canaccord Genuity Group Reiterates Buy Rating for Vertical Aerospace (NYSE:EVTL)
23 Dec 2024 07:46:12 By Buzz FX
-
Datadog (NASDAQ:DDOG) Given New $200.00 Price Target at Loop Capital
23 Dec 2024 07:41:13 By Buzz FX
-
Assam Tea industry facing crisis amid rising costs and declining exports, say ATPA
23 Dec 2024 07:40:22 By Buzz FX
-
Gold News: Fed’s Hawkish Stance Pressures Prices as Holiday Trading Stalls
23 Dec 2024 07:36:18 By Buzz FX
-
Viewpoint: China SiMn prices face pressure in 2025
23 Dec 2024 07:26:25 By Buzz FX
-
Sources: Fed's Barr Seeks Legal Advice Amid Trump Removal Speculation | Newsmax.com
23 Dec 2024 07:26:25 By Buzz FX
-
Rockwell Medical (NASDAQ:RMTI) Earns "Buy" Rating from HC Wainwright
23 Dec 2024 07:26:12 By Buzz FX
-
Telsey Advisory Group Reiterates Outperform Rating for Kroger (NYSE:KR)
23 Dec 2024 07:26:12 By Buzz FX
-
23 Dec 2024 07:26:12 By Buzz FX
-
HC Wainwright Increases SoundHound AI (NASDAQ:SOUN) Price Target to $26.00
23 Dec 2024 07:26:12 By Buzz FX
-
Lexicon Pharmaceuticals' (LXRX) Hold Rating Reaffirmed at Needham & Company LLC
23 Dec 2024 07:26:12 By Buzz FX
-
Rhythm Pharmaceuticals' (RYTM) Buy Rating Reaffirmed at HC Wainwright
23 Dec 2024 07:26:12 By Buzz FX
-
HC Wainwright Reiterates "Buy" Rating for BrainsWay (NASDAQ:BWAY)
23 Dec 2024 07:26:12 By Buzz FX
-
HC Wainwright Reaffirms "Buy" Rating for Vanda Pharmaceuticals (NASDAQ:VNDA)
23 Dec 2024 07:26:12 By Buzz FX
-
Mexico Prices Slow Less Than Expected, Backing Rate Cut Pace
23 Dec 2024 07:21:12 By Buzz FX
-
Carnival Co. & (NYSE:CCL) Given New $32.00 Price Target at Barclays
23 Dec 2024 07:16:12 By Buzz FX
-
Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $43.00 by Analysts at Truist Financial
23 Dec 2024 07:16:12 By Buzz FX
- <<
- <
- 1
- >